Amiodarone
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Documented life-threatening recurrent ventricular fibrillation not responding to other therapy (oral) | Adults | Monotherapy or adjunctive | FDA Approved |
| Documented life-threatening recurrent hemodynamically unstable VT not responding to other therapy (oral) | Adults | Monotherapy or adjunctive | FDA Approved |
| Initial treatment and prophylaxis of frequently recurring VF and hemodynamically unstable VT in patients refractory to other therapy (IV) | Adults requiring acute control | Acute IV monotherapy | FDA Approved |
Amiodarone is reserved by the FDA label for life-threatening ventricular arrhythmias because of its substantial long-term toxicity profile. In practice, however, amiodarone is the most-used antiarrhythmic worldwide and is prescribed off-label far more often than for its narrow approved indications. The 2017 AHA/ACC/HRS ventricular arrhythmia guideline and the 2023 ACC/AHA/ACCP/HRS atrial fibrillation guideline both endorse multiple off-label uses, and amiodarone (or lidocaine) remains a recommended antiarrhythmic during ACLS for shock-refractory VF and pulseless VT.
Atrial fibrillation — rhythm control and pharmacologic cardioversion (high-quality evidence): preferred agent in patients with structural heart disease or heart failure, where flecainide and propafenone are contraindicated.
Maintenance of sinus rhythm post-cardioversion (high-quality evidence): superior to sotalol and propafenone in the CTAF and SAFE-T trials.
Cardiac arrest from VF / pulseless VT (high-quality evidence): 300 mg IV/IO bolus per ACLS protocols; ARREST and ROC-ALPS trials assessed amiodarone in this setting.
Stable monomorphic VT with acceptable hemodynamics (moderate-quality evidence).
Pre-excited atrial fibrillation (low-quality evidence): controversial — many experts now favor procainamide or DC cardioversion; case reports of hemodynamic deterioration with amiodarone in this setting.
Pediatric supraventricular and ventricular arrhythmias (low-quality evidence): used commonly in pediatric cardiology despite limited RCT data.
Postoperative atrial fibrillation prophylaxis after cardiac surgery (high-quality evidence): supported by the PAPABEAR trial and meta-analyses.
Dosing
Amiodarone’s enormous volume of distribution and slow tissue saturation make its dosing fundamentally different from most antiarrhythmics: every chronic regimen requires a loading phase followed by a long taper to maintenance. The doses below are organized by clinical scenario rather than by tablet strength.
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Cardiac arrest — shock-refractory VF / pulseless VT | 300 mg IV/IO push | 150 mg IV/IO once for refractory arrhythmia | 2.2 g/24 h IV | Per AHA ACLS algorithm; given after the third defibrillation attempt; second dose after the fifth shock if VF/pVT persists. Lidocaine 1–1.5 mg/kg is an acceptable alternative. |
| Stable VT or recurrent VT/VF — IV initiation | 150 mg IV over 10 min | 1 mg/min × 6 h, then 0.5 mg/min × 18 h | 2.2 g over 24 h | Supplemental 150 mg infusions over 10 min may be given for breakthrough VT. Use central access for infusions exceeding 1 hour or concentrations >2 mg/mL; phlebitis is common with peripheral IV use. |
| Recurrent VT/VF — chronic oral suppression | 800–1600 mg/day PO in divided doses × 1–3 wk | 600–800 mg/day × ~1 month, then 400 mg/day | 400 mg/day chronic | Per Pacerone PI titration schedule. Use the lowest effective maintenance dose to limit organ toxicity. |
| Atrial fibrillation — rhythm control (outpatient oral load) | 600 mg/day PO × 4 wk (or 400 mg/day × 4 wk) | 200 mg/day | 400 mg/day | Off-label; common cumulative load ~10 g. Lower-dose load (400 mg/day × 4 wk) preferred for older or low-body-weight patients. |
| Atrial fibrillation — pharmacologic cardioversion (inpatient IV) | 5–7 mg/kg IV over 30–60 min | ~1 mg/min, transitioning to oral when feasible | 2.2 g/24 h IV | Off-label; conversion typically takes hours; rate control occurs earlier. Anticoagulation per CHA₂DS₂-VASc still required. |
| Post-cardiac surgery AF prophylaxis (PAPABEAR regimen) | 10 mg/kg/day PO in divided doses, starting 6 days preop | 10 mg/kg/day continued through postop day 6 | ~13 days total course | Off-label. Reduced postoperative AF incidence approximately by half versus placebo (PAPABEAR). Several alternative perioperative regimens exist; meta-analyses show similar efficacy at total cumulative doses of 5–10 g. |
Population-Specific Adjustments
| Population | Adjustment | Rationale |
|---|---|---|
| Renal impairment (any CrCl) | No dose change | Amiodarone undergoes negligible renal excretion; renal function does not influence its pharmacokinetics. |
| Hepatic impairment | No formal dose reduction defined; use lowest effective dose; monitor LFTs | Hepatic metabolism; AST/ALT >3× ULN warrants reduction or discontinuation. |
| Older adults (≥65 y) or low body weight | Start low; lower maintenance doses (e.g., 200 mg/day or below) | Reduced clearance (~100 vs 150 mL/hr/kg in younger adults); longer half-life and higher tissue exposure. |
| Pediatric (off-label; safety/efficacy not established) | IV: 5 mg/kg load over 20–60 min, then continuous infusion per institutional protocol | PALS supports 5 mg/kg IV/IO bolus for refractory pulseless VT/VF. |
Amiodarone’s onset of antiarrhythmic effect lags its first dose by days to weeks because the drug must saturate myocardium, fat, lung, and liver. Skipping the loading phase is a common cause of “amiodarone failure.” Because the terminal half-life averages around 58 days, amiodarone’s effects — including drug interactions — persist for weeks to months after discontinuation. This is critical when transitioning to another antiarrhythmic, planning ablation, or scheduling an interacting drug.
Pharmacology
Mechanism of Action
Amiodarone is an iodinated benzofuran derivative; its 37% iodine content by weight underlies several of its toxicities. Although classified as a Vaughan-Williams Class III agent because its dominant effect is potassium channel blockade and prolongation of the cardiac action potential, amiodarone exhibits properties of all four antiarrhythmic classes: Class I (sodium channel blockade in the inactivated state), Class II (non-competitive beta-adrenergic antagonism), Class III (delayed-rectifier potassium current inhibition), and Class IV (L-type calcium channel blockade). This polypharmacy underlies its broad-spectrum efficacy across atrial and ventricular arrhythmias and a relatively low propensity to cause torsades de pointes despite QT prolongation.
The active N-desethyl metabolite (DEA) accumulates in tissue at concentrations comparable to or higher than the parent compound and contributes substantially to chronic effect. Amiodarone also inhibits peripheral conversion of T4 to T3, accounting for the elevated reverse-T3 and modest TSH rise commonly observed early in therapy without true hypothyroidism.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Bioavailability ~50% (range 35–65%); Tmax 3–7 h; food increases absorption | Take consistently with regard to meals; switching is acceptable for tolerability, but consistency stabilizes plasma levels. |
| Distribution | Vd ~66 L/kg; protein binding ~96%; extensive accumulation in adipose tissue, liver, lung, and myocardium | Tissue saturation explains the multi-day onset and persistent effect for weeks to months after discontinuation. |
| Metabolism | Hepatic via CYP3A4 and CYP2C8 to N-desethylamiodarone (active); amiodarone inhibits CYP1A2, CYP2C9, CYP2D6, CYP3A4, and P-glycoprotein | Reciprocal interactions are extensive; CYP3A4 inducers (rifampin, St John’s wort) and inhibitors (cimetidine, grapefruit juice) significantly alter amiodarone exposure. |
| Elimination | Predominantly biliary/fecal; less than 1% excreted unchanged in urine; terminal half-life ~58 days mean (parent), ~36 days (DEA); not dialyzable | No renal dose adjustment; effects persist for months after stopping; hemodialysis cannot remove the drug. |
Side Effects
Amiodarone has the broadest organ-toxicity profile of any commonly prescribed cardiovascular drug. Most adverse effects are dose- and duration-dependent, and many do not appear until months or years into therapy. Modern low-dose maintenance regimens (≤200 mg/day) are associated with substantially lower toxicity rates than the high-dose regimens reported in older literature, but no dose is fully “safe.”
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Corneal microdeposits | >90% with chronic use | Visible on slit-lamp examination in nearly all chronic users; rarely cause halos or blurred vision and almost never require discontinuation. |
| Photosensitivity | ~25–75% | Phototoxic rather than allergic; severe sunburn-like reactions occur with brief sun exposure; counsel sunscreen and protective clothing. |
| Nausea, anorexia, constipation | ~25% | Most prominent during loading; mitigated by dividing doses and taking with food. |
| Tremor / ataxia / sleep disturbance | ~10–40% | Dose-related; often improve once maintenance dose drops below ~300 mg/day. |
| Asymptomatic AST/ALT elevation | ~15–30% | Usually transient and mild; persistent elevation >3× ULN warrants dose reduction or discontinuation. |
| Asymptomatic sinus bradycardia | Common, often dose-related | Frequently observed on ECG without symptoms; risk of symptomatic bradycardia or sinus arrest is 2–4% per FDA label. |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Hypothyroidism | ~6% | More common in iodine-replete regions; manage with levothyroxine without stopping amiodarone if therapy is essential. |
| Hyperthyroidism (AIT type 1 or 2) | ~2–3% | Higher in iodine-deficient regions; type 1 = iodine-induced overproduction, type 2 = destructive thyroiditis. Type 2 typically responds to corticosteroids. |
| Slate-gray / blue skin discoloration | Up to ~5–10% of long-term users | Develops with prolonged use, typically with high cumulative dose; partially reversible over months to years after stopping. |
| Symptomatic bradycardia / sinus arrest | 2–4% | Rate from FDA label; risk amplified by concurrent beta-blockers, non-DHP calcium channel blockers, or pre-existing sinus node disease. |
| Peripheral neuropathy / proximal myopathy | ~3–5% | Sensorimotor pattern; usually slowly reversible after discontinuation; consider EMG if progressive. |
| Phlebitis with IV use | ~5–9% | Use central access for infusions >1 h or concentrations >2 mg/mL; in-line filter recommended. |
| Hypotension with IV bolus | ~3–16% | Largely vehicle-related (polysorbate-80 in standard formulation); slow the infusion or switch to Nexterone (PVC-free, polysorbate-free). |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Pulmonary toxicity (interstitial pneumonitis, fibrosis, ARDS) | Historically up to 17% (high-dose era); ~1.6–5% with modern low-dose use | Months to years; rarely acute | Permanent discontinuation; high-dose corticosteroids if clinically significant; case fatality ~10%. |
| Hepatotoxicity (severe / fulminant) | Rare | Variable — acute (IV) or chronic | Stop drug if AST/ALT >3× ULN persistent or symptomatic; hospitalize for jaundice or coagulopathy. |
| Torsades de pointes / proarrhythmia | <1% (lower than expected for a class III agent) | Days to weeks of therapy | Discontinue; correct K⁺/Mg²⁺; IV magnesium for active TdP. |
| Optic neuropathy / optic neuritis | Rare | Months | Urgent ophthalmology referral; discontinue if confirmed; may cause permanent visual loss. |
| High-grade AV block (without pacemaker) | ~2–5% | Any time | Hold drug; assess pacemaker need; avoid concurrent rate-slowing agents. |
| Severe amiodarone-induced thyrotoxicosis | Rare | Months to years | Endocrinology consult; methimazole + glucocorticoids; thyroidectomy may be required for refractory cases. |
| Anaphylaxis / angioedema | Very rare | Any time | Emergency care; permanent discontinuation; iodine cross-reactivity possible. |
| Severe cutaneous reactions (SJS/TEN; very rare reports) | Very rare | Days to weeks | Immediate discontinuation; burn unit / dermatology consult. |
| Reason for Discontinuation | Approx. Incidence | Context |
|---|---|---|
| Pulmonary toxicity | Variable (dose-dependent) | Most common reason for permanent discontinuation in chronic users; rate substantially lower at modern low doses. |
| Thyroid dysfunction (hypo or hyper) | ~5–10% | Hypothyroidism is often managed with levothyroxine without stopping amiodarone; hyperthyroidism more often forces cessation. |
| Hepatic enzyme elevation >3× ULN | ~3–5% | Persistent rises despite dose reduction. |
| Neurologic symptoms (tremor, ataxia, neuropathy) | ~3–5% | Often improves with dose reduction before requiring stoppage. |
| Bradycardia / heart block | ~2–5% | Pacemaker may permit continued therapy in selected patients. |
Any new dyspnea, dry cough, or fall in DLCO during amiodarone therapy must trigger evaluation for pulmonary toxicity. Obtain CXR, high-resolution CT, and pulmonary function tests; differential includes heart failure, infection, and pulmonary embolism. If amiodarone pneumonitis is suspected, discontinue amiodarone immediately — the drug’s long half-life means clinical worsening can continue for weeks even after cessation. High-dose corticosteroids (typically prednisone 40–60 mg/day, tapered slowly over months) are the mainstay of treatment when toxicity is clinically significant.
Drug Interactions
Amiodarone is one of the most interaction-prone drugs in clinical use. It both inhibits and is metabolized by CYP3A4, CYP2C9, CYP2D6, and P-glycoprotein, and it shares pharmacodynamic risks (QT prolongation, AV nodal slowing, bradycardia) with many cardiovascular and psychotropic agents. Because amiodarone’s elimination half-life averages around 58 days, interactions persist for weeks to months after the drug is stopped.
Monitoring
Amiodarone requires the most extensive monitoring schedule of any commonly prescribed cardiovascular drug. The 2007 HRS expert consensus by Goldschlager and colleagues established the framework still in use today; institutions vary slightly in periodicity but agree on the parameters.
-
ECG (12-lead)
Baseline, then every 3–6 months
Routine Assess QT/QTc, heart rate, PR, AV block. Reduce dose or discontinue if QTc >500 ms or new advanced AV block; some QTc rise is expected with chronic therapy. -
Thyroid function (TSH ± free T4)
Baseline, every 6 months
Routine A modest TSH rise (typically <10 mIU/L) early in therapy reflects blocked T4→T3 conversion and may not require treatment. Frank hypo- or hyperthyroidism warrants endocrinology referral. -
Liver function (AST, ALT)
Baseline, every 6 months
Routine Mild elevations (<2× ULN) are common and usually transient. Persistent values >3× ULN, jaundice, or hepatomegaly require dose reduction or discontinuation. -
Chest X-ray
Baseline, repeat every 3–6 months per FDA PI
Routine New infiltrates or interstitial pattern raise suspicion for pulmonary toxicity; correlate with PFTs and HRCT when present. -
Pulmonary function tests + DLCO
Baseline; repeat if symptoms develop
Trigger-based A fall in DLCO of more than ~15–20% from baseline strongly suggests amiodarone pulmonary toxicity. Some clinicians repeat PFTs in long-term users with pre-existing lung disease. -
Ophthalmologic examination
If visual symptoms develop
Trigger-based Corneal microdeposits do not require workup unless visually significant. Any acute visual loss, scotoma, or optic disc swelling requires urgent ophthalmology evaluation for optic neuropathy. -
Skin examination
At each visit
Routine Note any slate-gray discoloration, severe phototoxic reactions, or bullous lesions; reinforce sun protection counselling. -
Serum electrolytes (K⁺, Mg²⁺)
If concurrent diuretics or symptoms
Trigger-based Hypokalemia and hypomagnesemia amplify QT prolongation and torsades risk; correct aggressively before continuing therapy. -
INR (if on warfarin)
Within 3–5 days of co-initiation, then weekly until stable
Routine Reduce warfarin dose at amiodarone initiation; effect peaks at several weeks and persists for months after stopping amiodarone. -
Digoxin level (if applicable)
Within 1 week of co-initiation
Routine Reduce digoxin dose by approximately half at amiodarone initiation; recheck level after 1 week, target trough 0.5–0.9 ng/mL.
A useful “amiodarone visit” template every 6 months: TSH, AST/ALT, basic metabolic panel, INR (if applicable), 12-lead ECG, focused symptom review (dyspnea, vision, weight change, tremor), and skin examination. CXR at baseline and periodically thereafter, with PFTs/DLCO triggered by symptoms or radiographic change, covers the highest-risk organ system.
Contraindications & Cautions
Reserve for life-threatening arrhythmias. Amiodarone hydrochloride should be used only in patients with documented life-threatening recurrent ventricular arrhythmias unresponsive to other available antiarrhythmics or when alternatives cannot be tolerated, because its use is accompanied by substantial toxicity.
Pulmonary toxicity: rates of pulmonary toxicity (hypersensitivity pneumonitis or interstitial/alveolar pneumonitis) have been reported as high as 17% in some series, with fatality in approximately 10% of cases when toxicity occurs. Pulmonary fibrosis can result. (Modern low-dose maintenance therapy carries a lower rate.)
Hepatotoxicity: rare cases of fatal hepatic failure have been reported. Asymptomatic enzyme elevation occurs frequently; persistent elevation greater than three times the upper limit of normal warrants dose reduction or discontinuation.
Proarrhythmia: amiodarone can worsen existing arrhythmias or precipitate new ones, including torsades de pointes. Initiate therapy in a clinical setting with continuous ECG monitoring and resuscitation capability when feasible.
Absolute Contraindications
- Cardiogenic shock
- Sick sinus syndrome with marked bradycardia (in absence of pacemaker)
- Second- or third-degree AV block (in absence of pacemaker)
- Bradycardia leading to syncope (in absence of pacemaker)
- Known hypersensitivity to amiodarone or any component (including iodine)
Relative Contraindications (Specialist Input Recommended)
- Pre-existing pulmonary disease (COPD, ILD, prior amiodarone pneumonitis) — pulmonologist input recommended; consider alternative agents
- Decompensated thyroid disease — endocrinology consultation; correct thyroid status before initiation when possible
- Severe hepatic impairment — hepatology input; lowest effective dose with frequent LFT monitoring
- Pregnancy — amiodarone may cause fetal harm (neonatal hypo- or hyperthyroidism, neonatal bradycardia, neurodevelopmental abnormalities, preterm birth, fetal growth restriction). Use only when potential maternal benefit clearly outweighs fetal risk in life-threatening ventricular arrhythmias.
- Concurrent QT-prolonging drugs that cannot be stopped (e.g., methadone in opioid maintenance) — cardiology and the prescribing specialty should jointly decide on combined use with telemetry
- Long QT syndrome (congenital or acquired) — generally avoid; alternatives such as beta-blockade or device therapy preferred
Use with Caution
- Older adults — reduced clearance and higher tissue exposure; greater bradycardia and neurologic effects; use lower maintenance doses
- Concurrent beta-blocker, verapamil, or diltiazem — additive AV nodal slowing; telemetry during initiation
- Iodine sensitivity or thyroid autoimmunity — higher risk of thyroid dysfunction
- Patients on warfarin or DOAC — bleeding risk amplified; see Drug Interactions
- Photosensitivity-prone or fair-skinned patients — counsel on rigorous sun protection
- Lactation — amiodarone and DEA pass into breast milk; breastfeeding is not recommended
Patient Counselling
Purpose of Therapy
Explain that amiodarone is a long-acting medication used to control serious heart rhythm problems. It works gradually over days to weeks because it builds up in body tissues, and it stays in the body for weeks to months after stopping. Frame the medication as effective but requiring active partnership in monitoring — most serious side effects can be detected early through scheduled testing.
How to Take
Tablets are usually taken once or twice daily. Take consistently with regard to meals — either always with food or always without — because food increases absorption. Doses missed by less than half the dosing interval can be taken when remembered; otherwise, skip the missed dose and resume the regular schedule. Patients should never double up. Avoid grapefruit and grapefruit juice for the duration of therapy. A wallet card or shared electronic medication list noting amiodarone use is helpful because of the long list of drug interactions and the need to inform anesthetists, surgeons, and other prescribers — even months after stopping the drug.
Sources
- Pacerone (amiodarone hydrochloride) tablets — full prescribing information. Upsher-Smith Laboratories. FDA label PDF Primary US prescribing information for oral amiodarone, including the boxed warning, dosing, and interaction tables cited throughout this monograph.
- Nexterone (amiodarone HCl) injection — full prescribing information. Baxter Healthcare. Available via DailyMed at dailymed.nlm.nih.gov Reference for the polysorbate-free, premixed IV formulation; relevant to the hypotension and phlebitis profile.
- FDA Drug Safety Communication. FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another direct acting antiviral drug. March 24, 2015. fda.gov Source for the major bradycardia interaction warning between amiodarone and sofosbuvir-containing HCV regimens.
- Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation (ARREST). N Engl J Med. 1999;341(12):871–878. doi:10.1056/NEJM199909163411203 Landmark RCT showing improved survival to hospital admission with IV amiodarone in shock-refractory VF.
- Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation (ALIVE). N Engl J Med. 2002;346(12):884–890. doi:10.1056/NEJMoa013029 Comparative trial supporting amiodarone over lidocaine for survival to admission after refractory VF arrest.
- Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation (CTAF). N Engl J Med. 2000;342(13):913–920. doi:10.1056/NEJM200003303421302 Demonstrated superiority of amiodarone over sotalol/propafenone for AF rhythm-control maintenance.
- Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation (SAFE-T). N Engl J Med. 2005;352(18):1861–1872. doi:10.1056/NEJMoa041705 Definitive head-to-head trial confirming amiodarone’s higher efficacy in maintaining sinus rhythm.
- Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure (SCD-HeFT). N Engl J Med. 2005;352(3):225–237. doi:10.1056/NEJMoa043399 Showed amiodarone did not improve survival in HFrEF compared with placebo, contextualizing its role versus ICDs.
- Mitchell LB, Exner DV, Wyse DG, et al. Prophylactic oral amiodarone for the prevention of arrhythmias that begin early after revascularization, valve replacement, or repair (PAPABEAR): a randomized controlled trial. JAMA. 2005;294(24):3093–3100. doi:10.1001/jama.294.24.3093 Defines the perioperative 10 mg/kg/day regimen for postoperative AF prophylaxis used in the dosing table.
- Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. Circulation. 2024;149(1):e1–e156. doi:10.1161/CIR.0000000000001193 Current US guideline framing amiodarone’s preferred role in AF rhythm control for patients with structural heart disease.
- Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation. 2018;138(13):e272–e391. doi:10.1161/CIR.0000000000000549 Defines class of recommendation for amiodarone in stable VT, electrical storm, and as an ICD adjunct.
- Panchal AR, Bartos JA, Cabañas JG, et al. Part 3: adult basic and advanced life support — 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2020;142(16 suppl 2):S366–S468. doi:10.1161/CIR.0000000000000916 Source for the ACLS bolus and follow-up dosing of amiodarone in cardiac arrest.
- Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone — 2007. Heart Rhythm. 2007;4(9):1250–1259. doi:10.1016/j.hrthm.2007.07.020 HRS expert consensus that established the routine monitoring framework still used today.
- Wiggins BS, Saseen JJ, Page RL II, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134(21):e468–e495. doi:10.1161/CIR.0000000000000456 Source for the simvastatin (≤20 mg/day) and lovastatin (≤40 mg/day) dose limits with amiodarone.
- Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res. 1997;35(1):13–29. doi:10.1016/S0008-6363(97)00114-4 Foundational review explaining amiodarone’s multichannel effects across all four Vaughan-Williams classes.
- Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 2007;298(11):1312–1322. doi:10.1001/jama.298.11.1312 Practical synthesis of efficacy and toxicity data informing clinical decision making.
- Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet. 1984;9(2):136–156. doi:10.2165/00003088-198409020-00002 Reference paper defining amiodarone’s volume of distribution, elimination half-life, and tissue accumulation.
- Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J. 2009;16(2):43–48. doi:10.1155/2009/282540 Clinical review describing the spectrum, risk factors, and management of amiodarone-induced lung disease, including data on rates at modern lower doses.
- Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med. 1991;91(5):507–511. doi:10.1016/0002-9343(91)90187-3 Defines regional and individual predictors of amiodarone-induced thyroid dysfunction.